Vanda Pharmaceuticals | VNDA - Net Income


Vanda Pharmaceuticals reported $-18.9M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -132.73M 163.54M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
J&J USD 5.24B 119M Mar/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Ligand Pharmaceuticals USD -13.34M 58.13M Mar/2026
Merck USD -4.24B 7.2B Mar/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Takeda JPY -24.32B 127.96B Mar/2026
Teva Pharmaceutical Industries USD 369M 111M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Veracyte USD 28.71M 12.44M Mar/2026